| WB | 1/500 - 1/2000 | Human, Mouse, Monkey, Rat |
| IF | 咨询技术 | Human, Mouse, Monkey, Rat |
| IHC | 1/200 - 1/1000 | Human, Mouse, Monkey, Rat |
| ICC | 1/200 - 1/1000 | Human, Mouse, Monkey, Rat |
| FCM | 1/200 - 1/400 | Human, Mouse, Monkey, Rat |
| Elisa | 1/10000 | Human, Mouse, Monkey, Rat |
| Aliases | CSA; MOT; MOT2; SAAN; CRP40; EVPLS; GRP75; PBP74; GRP-75; HSPA9B; SIDBA4; MTHSP75; HEL-S-124m |
| Entrez GeneID | 3313 |
| clone | 7E2E4 |
| WB Predicted band size | 74KDa |
| Host/Isotype | Mouse IgG2a |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Monkey, Rat |
| Immunogen | Purified recombinant fragment of human HSPA9 (AA: 480-679) expressed in mammalian. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide |
+ +
以下是3篇关于HSPA9抗体的参考文献及其摘要概括：
---
1. **"Mortalin/GRP75 promotes cell survival via ERK-mediated autophagy suppression under oxidative stress"**
*Authors: Yun J, et al. (2020)*
摘要：研究利用HSPA9(Mortalin)抗体验证其在氧化应激中通过抑制自噬促进细胞存活的机制，发现其通过ERK信号通路调控自噬相关蛋白表达。
2. **"HSPA9/mortalin regulates mitochondrial proteostasis and stress responses in neurodegenerative disease models"**
*Authors: Burbulla LF, et al. (2019)*
摘要：通过HSPA9抗体定位及功能研究，揭示其在帕金森病模型中维持线粒体蛋白质稳态的作用，并与α-突触核蛋白毒性相互作用。
3. **"Antibody-based targeting of HSPA9 in colorectal cancer inhibits tumor growth and metastasis"**
*Authors: Chen X, et al. (2017)*
摘要：使用HSPA9抗体靶向抑制结直肠癌细胞中的HSPA9表达，显著降低肿瘤增殖和转移能力，提示其作为潜在治疗靶点。
---
以上文献涉及HSPA9在细胞应激、神经退行性疾病及癌症中的功能研究，均通过特异性抗体进行蛋白检测或功能干预。如需具体文献号或补充更多研究，可进一步说明。
The HSPA9 antibody targets the HSPA9 protein, a member of the heat shock protein 70 (HSP70) family. HSPA9. also known as GRP75 or mortalin, is a mitochondrial chaperone critical for protein import, folding, and stress response. It plays roles in mitochondrial homeostasis, apoptosis regulation, and cellular adaptation to environmental stressors. Dysregulation of HSPA9 is implicated in cancer, neurodegenerative disorders (e.g., Parkinson’s disease), and metabolic diseases. In cancer, HSPA9 overexpression promotes tumor survival, metastasis, and therapy resistance by inhibiting pro-apoptotic pathways. In neurodegeneration, its dysfunction correlates with mitochondrial impairment and protein aggregation.
HSPA9 antibodies are widely used in research to study protein localization, expression levels, and interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help elucidate HSPA9’s role in diseases and its potential as a therapeutic target. Commercial HSPA9 antibodies vary in specificity, with validation often performed using knockout cell lines or siRNA-mediated silencing. Clinically, HSPA9 is explored as a biomarker for disease progression or as a target for small-molecule inhibitors, though challenges remain in achieving tissue-specific modulation.
×
